Trial Profile
A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs FS-118 (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Haematological malignancies; Head and neck cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors F-star; F-star Therapeutics; invoX Pharma
- 13 Jul 2023 Paclitaxel has been added as a primary drug to the treatment regimen, patient enrollment is increased. "Expansion cohort (FS118 + paclitaxel): Incidence of Treatment Emergent Adverse Events" is added as one more primary end-point. Invox pharma has replaced F-star Therapeutics as the sponsor of this study, France is added to locations thus making it a multinational study.
- 13 Jul 2023 Planned number of patients changed from 80 to 95.
- 13 Jul 2023 Planned End Date changed from 1 Dec 2022 to 1 Jun 2024.